Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical trial NCT05520138 · COMPLETED

Trial details

NCT number: NCT05520138
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

Prostatic Neoplasms, Castration-Resistant

Start date: 2022-08-29
Primary completion: 2023-06-30
Enrollment: 5506

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.